NZ565112A - New pharmaceutical compounds - Google Patents

New pharmaceutical compounds

Info

Publication number
NZ565112A
NZ565112A NZ565112A NZ56511206A NZ565112A NZ 565112 A NZ565112 A NZ 565112A NZ 565112 A NZ565112 A NZ 565112A NZ 56511206 A NZ56511206 A NZ 56511206A NZ 565112 A NZ565112 A NZ 565112A
Authority
NZ
New Zealand
Prior art keywords
nitro
dihydroxy
benzo
compound
alkyl
Prior art date
Application number
NZ565112A
Other languages
English (en)
Inventor
Marko Ahlmark
Reijo Backstrom
Anne Luiro
Jarmo Pystynen
Eija Tiainen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of NZ565112A publication Critical patent/NZ565112A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/84—Naphthothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/89—Benzo [c] furans; Hydrogenated benzo [c] furans with two oxygen atoms directly attached in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NZ565112A 2005-07-18 2006-07-17 New pharmaceutical compounds NZ565112A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69989805P 2005-07-18 2005-07-18
PCT/FI2006/000257 WO2007010085A2 (en) 2005-07-18 2006-07-17 New pharmaceutical compounds

Publications (1)

Publication Number Publication Date
NZ565112A true NZ565112A (en) 2010-09-30

Family

ID=37500024

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ565112A NZ565112A (en) 2005-07-18 2006-07-17 New pharmaceutical compounds

Country Status (26)

Country Link
US (1) US8318785B2 (xx)
EP (1) EP1910325B1 (xx)
JP (1) JP5015152B2 (xx)
KR (1) KR20080035571A (xx)
CN (1) CN101282957B (xx)
AR (1) AR058800A1 (xx)
AT (1) ATE483702T1 (xx)
AU (1) AU2006271631B2 (xx)
BR (1) BRPI0613778A2 (xx)
CA (1) CA2615466C (xx)
DE (1) DE602006017378D1 (xx)
DK (1) DK1910325T3 (xx)
EA (1) EA017329B1 (xx)
EC (1) ECSP088156A (xx)
ES (1) ES2354114T3 (xx)
GE (1) GEP20115222B (xx)
IL (1) IL188438A (xx)
MX (1) MX2008000875A (xx)
MY (1) MY148644A (xx)
NO (1) NO20080779L (xx)
NZ (1) NZ565112A (xx)
PE (1) PE20070206A1 (xx)
TW (1) TW200745074A (xx)
UA (1) UA98608C2 (xx)
WO (1) WO2007010085A2 (xx)
ZA (1) ZA200800368B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5369854B2 (ja) 2008-04-21 2013-12-18 住友化学株式会社 有害節足動物防除組成物および縮合複素環化合物
JP5540640B2 (ja) 2009-10-07 2014-07-02 住友化学株式会社 複素環化合物及びその有害節足動物防除用途
MX336187B (es) 2010-03-04 2016-01-07 Orion Corp Metodo para tratar el mal de parkinson.
CN103037694B (zh) 2010-06-23 2014-08-13 住友化学株式会社 防治有害节肢动物的组合物和杂环化合物
WO2012013614A1 (en) * 2010-07-27 2012-02-02 F. Hoffmann-La Roche Ag Method for the identification of catechol o-methyltransferase modulators
CN106986862A (zh) 2010-12-22 2017-07-28 Abbvie 公司 丙型肝炎抑制剂及其用途
TWI638802B (zh) 2012-05-24 2018-10-21 芬蘭商奧利安公司 兒茶酚ｏ－甲基轉移酶活性抑制化合物
KR101551313B1 (ko) * 2014-07-28 2015-09-09 충남대학교산학협력단 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
CA3007458A1 (en) * 2015-12-18 2017-06-22 Hubert Koester Bicyclic-compounds for use as a medicament, in particular for trea tment of parkinson's disease
GB201617339D0 (en) 2016-10-12 2016-11-23 Lytix Biopharma As Therapeutic compounds
CN111253335B (zh) * 2020-03-12 2023-06-06 浙江扬帆新材料股份有限公司 一种n-取代苯并异噻唑啉-3-酮衍生物的新合成方法
CN113121472B (zh) * 2021-03-05 2022-12-16 上海应用技术大学 一种利用金配合物制备n-磺酰基四氢吡咯类化合物的方法
CN115286594B (zh) * 2022-07-24 2023-07-25 浙江工业大学 一种以s8为原料合成醌并噻唑类化合物的方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3973608A (en) * 1973-08-01 1976-08-10 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Microbial production of certain isoflavones
US4198415A (en) * 1979-01-22 1980-04-15 Eli Lilly And Company Prolactin inhibiting octahydro pyrazolo[3,4-g]quinolines
GB8406906D0 (en) * 1984-03-16 1984-04-18 Akzo Nv Benzo-thiazole and benzothiophene derivatives
CA1281325C (en) 1984-06-20 1991-03-12 Patrice C. Belanger Benzofuran derivatives
US5236952A (en) * 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
DE3832846A1 (de) 1988-09-28 1990-03-29 Bayer Ag Verwendung von benzothiophen-2-carboxamid-s,s-dioxiden zur behandlung von krankheiten
DE3832848A1 (de) 1988-09-28 1990-03-29 Bayer Ag Benzothiophen-2-carboxamid-s,s-dioxide
US5446294A (en) * 1991-07-31 1995-08-29 Texas Instruments Incorporated Microwave heterojunction bipolar transistors suitable for low-power, low-noise and high-power applications and method for fabricating same
JP3272819B2 (ja) 1993-06-16 2002-04-08 協和醗酵工業株式会社 安息香酸およびニコチン酸誘導体の製造方法
US5426191A (en) * 1993-12-03 1995-06-20 Warner-Lambert Company Process for the synthesis of 3-chlorobenzo[b]thiophene-2-carbonyl chlorides
GB9414139D0 (en) 1994-07-13 1994-08-31 Smithkline Beecham Plc Novel compounds
US5863936A (en) * 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
GB9510481D0 (en) * 1995-05-24 1995-07-19 Orion Yhtymae Oy New catechol derivatives
DE19545465A1 (de) 1995-12-06 1997-06-12 Bayer Ag Verfahren zur Herstellung von Benzothiophen-Derivaten
GB9626472D0 (en) * 1996-12-20 1997-02-05 Aperia Anita C New use of comt inhibitors
SE9701681D0 (sv) 1997-05-05 1997-05-05 Astra Ab New compounds
HN1999000146A (es) 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
GB2344819A (en) * 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
AU5319700A (en) 1999-06-02 2000-12-18 S. Mbua Ngale Efange Nicotine receptor ligands
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
AU7939200A (en) 1999-11-01 2001-05-14 Clariant Finance (Bvi) Limited Use of phthalides in stabiliser mixtures for organic materials
FI20000635A0 (fi) * 2000-03-17 2000-03-17 Orion Yhtymae Oyj COMT-inhibiittoreiden käyttö analgeettina
GB2363792A (en) 2000-06-21 2002-01-09 Portela & Ca Sa Nitrocatechols
GB0015228D0 (en) 2000-06-21 2000-08-16 Portela & Ca Sa Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders
FI20001593A (fi) * 2000-07-03 2002-01-04 Orion Yhtymo Oyj Comt-entsyymiõ inhiboivaa aktiivisuutta omaavia kumariinijohdannaisia
FI20002044A0 (fi) * 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
EP1444204A4 (en) 2001-10-22 2009-11-04 Univ New York State Res Found INHIBITORS OF PROTEIN KINASES AND PROTEINS PHOSPHATASES, METHODS OF IDENTIFICATION AND METHODS OF USE THEREOF
WO2003062392A2 (en) 2002-01-18 2003-07-31 Ceretek Llc Methods of treating conditions associated with an edg receptor
AU2003207774A1 (en) * 2002-01-30 2003-09-02 Montana State University Pestalotiopsis microsporia isolates and compounds derived therefrom
DE10210779A1 (de) 2002-03-12 2003-10-09 Merck Patent Gmbh Cyclische Amide
CA2504344A1 (en) 2002-11-01 2004-05-21 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
GB0308025D0 (en) 2003-04-07 2003-05-14 Glaxo Group Ltd Compounds
EP1636210A1 (en) 2003-06-05 2006-03-22 Warner-Lambert Company LLC Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents
CA2528538A1 (en) 2003-06-19 2004-12-29 Psychiatric Genomics, Inc. Dual function compounds and uses thereof
JP2005145859A (ja) 2003-11-13 2005-06-09 Nippon Steel Chem Co Ltd 脱水素化方法及び芳香族複素環化合物の製造方法
CA2548300A1 (en) 2003-12-19 2005-06-30 F. Hoffmann-La Roche Ag Comt inhibitors
KR20050110955A (ko) 2004-05-20 2005-11-24 금호석유화학 주식회사 포토레지스트용 스트리퍼 조성물 및 이를 포토레지스트박리에 사용하는 방법
EP1812070B1 (en) 2004-11-10 2013-10-02 Orion Corporation Treatment of restless legs syndrome

Also Published As

Publication number Publication date
US20110086852A2 (en) 2011-04-14
PE20070206A1 (es) 2007-05-06
EP1910325A2 (en) 2008-04-16
DK1910325T3 (da) 2011-01-24
ZA200800368B (en) 2009-08-26
EP1910325B1 (en) 2010-10-06
JP5015152B2 (ja) 2012-08-29
ECSP088156A (es) 2008-02-20
BRPI0613778A2 (pt) 2011-02-01
CN101282957B (zh) 2013-07-10
IL188438A (en) 2013-07-31
DE602006017378D1 (de) 2010-11-18
KR20080035571A (ko) 2008-04-23
WO2007010085A2 (en) 2007-01-25
MX2008000875A (es) 2008-03-26
AU2006271631A1 (en) 2007-01-25
ES2354114T3 (es) 2011-03-10
CA2615466C (en) 2013-10-01
AR058800A1 (es) 2008-02-27
GEP20115222B (en) 2011-05-25
CN101282957A (zh) 2008-10-08
NO20080779L (no) 2008-02-13
IL188438A0 (en) 2008-11-03
AU2006271631B2 (en) 2011-05-12
ATE483702T1 (de) 2010-10-15
CA2615466A1 (en) 2007-01-25
MY148644A (en) 2013-05-15
UA98608C2 (xx) 2012-06-11
TW200745074A (en) 2007-12-16
EA200800357A1 (ru) 2008-06-30
JP2009501769A (ja) 2009-01-22
US20090209532A1 (en) 2009-08-20
WO2007010085A3 (en) 2007-03-29
US8318785B2 (en) 2012-11-27
EA017329B1 (ru) 2012-11-30

Similar Documents

Publication Publication Date Title
AU2006271631B2 (en) New pharmaceutical compounds
Zheng et al. Structure–activity relationship study of a novel necroptosis inhibitor, necrostatin-7
Lu et al. Synthesis and evaluation of anti-tubercular and antibacterial activities of new 4-(2, 6-dichlorobenzyloxy) phenyl thiazole, oxazole and imidazole derivatives. Part 2
AU2010301675B2 (en) Novel phenol derivative
JPH0588232B2 (xx)
EP2855426A1 (en) Catechol o-methyltransferase activity inhibiting compounds
JP6967632B2 (ja) ヒストンデメチラーゼ阻害剤
CN107176932B (zh) 苯并恶嗪酮衍生物及其制备方法和用途
JP2014514257A (ja) 選択的１７ベータ−ヒドロキシステロイドデヒドロゲナーゼ２型阻害剤としてのビアリール誘導体
JPWO2010007943A1 (ja) 含窒素複素環化合物
WO2010007944A1 (ja) 含窒素二環性複素環化合物
KR20080015788A (ko) ＧｌｙＲ의 조정제 또는 아고니스트인 벤조산 유도체
EP3091005A1 (en) 1,2-naphthoquinone derivative and method for preparing same
EP1317411A1 (en) Derivatives of naphthalene with comt inhibiting activity
Ma et al. Design, synthesis and biological evaluation of 4-aryl-5-aminoalkyl-thiazole-2-amines derivatives as ROCK II inhibitors
González et al. Novel thiophenes and analogues with anthelmintic activity against Haemonchus contortus
Sunder et al. Synthesis of novel N-(3-chloro-4-flurophenyl)-2-(5-((3-(4-hydroxy-2, 2-dimethyl-2, 3-dihydrobenzofuran-5-yl)-1-phenyl-1H-pyrazol-4-yl) methylene)-4-oxo-2-thioxothiazolidin-3-yl) acetamides having anti-inflammatory activity
Politanskaya et al. Directed synthesis of fluorine containing 2, 3-dihydrobenzo [b][1, 4] oxathiine derivatives from polyfluoroarenes
Alagarsamy et al. Synthesis and Pharmacological Investigation of 3‐Subsituted‐amino‐2‐methylsulfanyl‐5, 6, 7, 8‐tetrahydro‐3H‐benzo [4, 5] thieno [2, 3‐d] pyrimidin‐4‐ones as Analgesic and Anti‐Inflammatory Agents
JP3166092B2 (ja) クマリン誘導体及びそれらの用途
WO2013059984A1 (zh) 甲基丙烯酰基苯并咪唑（硫）酮衍生物及其作为抗菌药物的用途

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: ORION CORPORATION, FI

Free format text: OLD OWNER(S): ORION CORPORATION; REIJO BACKSTROM

Owner name: ORION CORPORATION, FI

Free format text: OLD OWNER(S): ORION CORPORATION; ORION CORPORATION

S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: CHAIN OF TITLE (71) TO INCLUDED INVENTORS (72) AS THE ORIGINAL APPLICANTS, THE APPLICATION HAS SUBSEQUENT BEEN ASSIGNED TO THE CURRENT APPLICANT (71)

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 JUL 2016 BY DENNEMEYER SA

Effective date: 20130608

LAPS Patent lapsed